The deal also establishes a new subsidiary, Excellos Labs, which will oversee continued operations in San Diego
This positions its platform as a rapidly evolving engine for next-generation genetic medicine
The platform combines internally developed technologies, strategic partnerships, and external AI capabilities
The global pharmaceutical company has been featured in both the DJBIC World Index and the DJBIC Emerging Markets Index
Access to genomic testing, not therapy cost, is the biggest challenge
US formulations grew 11% to Rs. 564 crore as Alembic enters US branded pharmaceuticals market with launch of Pivya
Company enters women’s personal grooming segment while strengthening pain management portfolio with herbal Ortho Oil
FY26 revenue rises to Rs. 4,359 crore as India’s leading CDMO strengthens global footprint with EU GMP certifications, UK MHRA approval and Europe supplies
Ex-US revenue rose sharply by 21% YoY to Rs. 2, 240.4 crore ($254 million); Operational PAT grew 50.3% YoY to Rs. 518.1 crore
The 38% adjusted EBITDA margin of base business has been supported by robust growth in the CDMO segment
Subscribe To Our Newsletter & Stay Updated
